Management of HCV transplant patients with triple therapy

Area of Science:

• Hepatology
• Virology
• Transplantation Medicine

Background:

• Hepatitis C virus (HCV) is a primary cause of end-stage liver disease and the leading indication for liver transplantation (LT).
• Graft reinfection with HCV is universal in LT recipients with detectable HCV RNA, leading to cirrhosis in 20-30% within 5 years.
• Decompensated cirrhosis post-LT has a severe prognosis, with approximately 40% decompensation within 1 year, often necessitating retransplantation.

Purpose of the Study:

• To evaluate the efficacy and safety of triple therapy using boceprevir (BOC) or telaprevir (TVR) in liver transplant recipients.
• To discuss the implications of direct-acting antivirals (DAAs) in managing HCV in LT patients.
• To comment on future therapeutic strategies for HCV in liver transplant recipients.

Main Methods:

• Review of triple therapy outcomes with boceprevir (BOC) or telaprevir (TVR).
• Assessment of efficacy and safety profiles of these direct-acting antiviral (DAA) regimens.
• Discussion of potential drug interactions, particularly with calcineurin inhibitors.

Main Results:

• Sustained virological response (SVR) with standard therapy (pegylated interferon and ribavirin) occurs in only 30% of LT patients.
• Direct-acting antivirals (DAAs) represent a new therapeutic era for HCV, but pose safety and tolerance challenges.
• Potential interactions between DAAs and calcineurin inhibitors are a significant concern in LT recipients.

Conclusions:

• While DAAs offer a new frontier in HCV treatment post-LT, their use requires careful consideration of safety and drug interactions.
• Optimizing antiviral therapy in LT recipients is crucial for improving graft and patient survival.
• Further research into safe and effective DAA strategies is needed for liver transplant recipients.